Page 433 - Williams Hematology ( PDFDrive )

408 Part V: Therapeutic Principles

93. Granger CB, Alexander JH, McMurray JJ, et al: Apixaban versus warfarin in patients 121. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspi-
with atrial fibrillation. N Engl J Med 365(11):981–992, 2011. rin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
94. Connolly SJ, Eikelboom J, Joyner C, et al: Apixaban in patients with atrial fibrillation. N Lancet 348(9038):1329–1339, 1996.
Engl J Med 364(9):806–817, 2011. 122. Yusuf S, Zhao F, Mehta SR, et al: Effects of clopidogrel in addition to aspirin in
95. Agnelli G, Buller HR, Cohen A, et al: Oral apixaban for the treatment of acute venous patients with acute coronary syndromes without ST-segment elevation. N Engl J Med
thromboembolism. N Engl J Med 369(9):799–808, 2013. 345(7):494–502, 2001.
96. Agnelli G, Buller HR, Cohen A, et al: Apixaban for extended treatment of venous 123. Bellemain-Appaix A, O’Connor SA, Silvain J, et al: Association of clopidogrel pretreat-
thromboembolism. N Engl J Med 368(8):699–708, 2013. ment with mortality, cardiovascular events, and major bleeding among patients under-
97. Lassen MR, Gallus A, Raskob GE, et al: Apixaban versus enoxaparin for thrombopro- going percutaneous coronary intervention: A systematic review and meta-analysis.
phylaxis after hip replacement. N Engl J Med 363(26):2487–2498, 2010. JAMA 308(23):2507–2516, 2012.
98. Lassen MR, Raskob GE, Gallus A, et al: Apixaban or enoxaparin for thromboprophy- 124. Sabatine MS: Novel antiplatelet strategies in acute coronary syndromes. Cleve Clin J
laxis after knee replacement. N Engl J Med 361(6):594–604, 2009. Med 76(Suppl 1):S8–S15, 2009.
99. Lassen MR, Raskob GE, Gallus A, et al: Apixaban versus enoxaparin for thrombopro- 125. Wiviott SD, Braunwald E, McCabe CH, et al: Prasugrel versus clopidogrel in patients
phylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lan- with acute coronary syndromes. N Engl J Med 357(20):2001–2015, 2007.
cet 375(9717):807–815, 2010. 126. Wallentin L, Becker RC, Budaj A, et al: Ticagrelor versus clopidogrel in patients with
100. Ogata K, Mendell-Harary J, Tachibana M, et al: Clinical safety, tolerability, pharmacok- acute coronary syndromes. N Engl J Med 361(11):1045–1057, 2009.
inetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy 127. Bhatt DL, Lincoff AM, Gibson CM, et al: Intravenous platelet blockade with cangrelor
volunteers. J Clin Pharmacol 50(7):743–753, 2010. during PCI. N Engl J Med 361(24):2330–2341, 2009.
101. Giugliano RP, Ruff CT, Braunwald E, et al: Edoxaban versus warfarin in patients with 128. Harrington RA, Stone GW, McNulty S, et al: Platelet inhibition with cangrelor in
atrial fibrillation. N Engl J Med 369(22):2093–2104, 2013. patients undergoing PCI. N Engl J Med 361(24):2318–2329, 2009.
102. Hokusai-VTE Investigators, Büller HR, Décousus H, et al: Edoxaban versus warfarin 129. Bhatt DL, Stone GW, Mahaffey KW, et al: Effect of platelet inhibition with cangrelor
for the treatment of symptomatic venous thromboembolism. N Engl J Med 369(15): during PCI on ischemic events. N Engl J Med 368(14):1303–1313, 2013.
1406–1415, 2013. 130. Steg PG, Bhatt DL, Hamm CW, et al: Effect of cangrelor on periprocedural outcomes
103. Hilleman DE, Dunlay RW, Packard KA: Reteplase for dysfunctional hemodialysis cath- in percutaneous coronary interventions: A pooled analysis of patient-level data. Lancet
eter clearance. Pharmacotherapy 23(2):137–141, 2003. 382(9909):1981–1992, 2013.
104. Van de Werf FJ, Topol EJ, Sobel BE: The impact of fibrinolytic therapy for ST-segment- 131. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa
elevation acute myocardial infarction. J Thromb Haemost 7(1):14–20, 2009. receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med
105. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. 330(14):956–961, 1994.
Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). 132. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose
Lancet 1(8478):397–402, 1986. heparin during percutaneous coronary revascularization. N Engl J Med 336(24):
106. Enden T, Haig Y, Kløw NE, et al: Long-term outcome after additional catheter-directed 1689–1696, 1997.
thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the 133. EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-
CaVenT study): A randomised controlled trial. Lancet 379(9810):31–38, 2012. controlled trial to assess safety of coronary stenting with use of platelet glycopro-
107. You JJ, Singer DE, Howard PA, et al: Antithrombotic therapy for atrial fibrillation: tein-IIb/IIIa blockade. Lancet 352(9122):87–92, 1998.
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College 134. Adams HP Jr, Effron MB, Torner J, et al: Emergency administration of abciximab for
of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl) treatment of patients with acute ischemic stroke: Results of an international phase III
:e531S-e575S, 2012. trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 39(1):
108. Brighton TA, Eikelboom JW, Mann K, et al: Low-dose aspirin for preventing recurrent 87–99, 2008.
venous thromboembolism. N Engl J Med 367(21):1979–1987, 2012. 135. Randomised placebo-controlled trial of effect of eptifibatide on complications of per-
109. Becattini C, Agnelli G, Schenone A, et al: Aspirin for preventing the recurrence of cutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggrega-
venous thromboembolism. N Engl J Med 366(21):1959–1967, 2012. tion and Coronary Thrombosis-II. Lancet 349(9063):1422–1428, 1997.
110. Jessup M, Antman E: Reducing the risk of heart attack and stroke: The American 136. Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al: Tirofiban as adjunctive therapy for
Heart Association/American College of Cardiology prevention guidelines. Circulation acute coronary syndromes and percutaneous coronary intervention: A meta-analysis
130(6):e48–e50, 2014. of randomized trials. Eur Heart J 31(1):35–49, 2010.
111. Kernan WN, Ovbiagele B, Black HR, et al: Guidelines for the prevention of stroke in 137. Tricoci P, Huang Z, Held C, et al: Thrombin-receptor antagonist vorapaxar in acute
patients with stroke and transient ischemic attack: A guideline for healthcare profes- coronary syndromes. N Engl J Med 366(1):20–33, 2012.
sionals from the American Heart Association/American Stroke Association. Stroke 138. Morrow DA, Braunwald E, Bonaca MP, et al: Vorapaxar in the secondary prevention of
45(7):2160–2236, 2014. atherothrombotic events. N Engl J Med 366(15):1404–1413, 2012.
112. Sacco RL, Diener HC, Yusuf S, et al: Aspirin and extended-release dipyridamole versus 139. Goto S, Ogawa H, Takeuchi M, et al: Double-blind, placebo-controlled Phase II studies
clopidogrel for recurrent stroke. N Engl J Med 359(12):1238–1251, 2008. of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients
113. Li X, Zhou G, Zhou X, Zhou S: The efficacy and safety of aspirin plus dipyridamole with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J
versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of ran- 31(21):2601–2613, 2010.
domized controlled trials. J Neurol Sci 332(1–2):92–96, 2013. 140. Eriksson BI, Dahl OE, Rosencher N, et al: Dabigatran etexilate versus enoxaparin for
114. Huang Y, Cheng Y, Wu J, et al: Cilostazol as an alternative to aspirin after ischaemic prevention of venous thromboembolism after total hip replacement: A randomised,
stroke: A randomised, double-blind, pilot study. Lancet Neurol 7(6):494–499, 2008. double-blind, non-inferiority trial. Lancet 370(9591):949–956, 2007.
115. Shinohara Y, Katayama Y, Uchiyama S, et al: Cilostazol for prevention of secondary 141. Eriksson BI, Dahl OE, Huo MH, et al: Oral dabigatran versus enoxaparin for throm-
stroke (CSPS 2): An aspirin-controlled, double-blind, randomised non-inferiority trial. boprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised,
Lancet Neurol 9(10):959–968, 2010. double-blind, non-inferiority trial. Thromb Haemost 105(4):721–729, 2011.
116. Thompson PD, Zimet R, Forbes WP, Zhang P: Meta-analysis of results from eight ran- 142. Eriksson BI, Dahl OE, Rosencher N, et al: Oral dabigatran etexilate vs. subcutaneous
domized, placebo-controlled trials on the effect of cilostazol on patients with intermit- enoxaparin for the prevention of venous thromboembolism after total knee replace-
tent claudication. Am J Cardiol 90(12):1314–1319, 2002. ment: The RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185, 2007.
117. Jull A, Arroll B, Parag V, Waters J: Pentoxifylline for treating venous leg ulcers. Cochrane 143. Mega JL, Braunwald E, Wiviott SD, et al: Rivaroxaban in patients with a recent acute
Database Syst Rev (3):CD001733, 2007. coronary syndrome. N Engl J Med 366(1):9–19, 2012.
118. Gent M, Blakely JA, Easton JD, et al: The Canadian American Ticlopidine Study (CATS) 144. Kakkar AK, Brenner B, Dahl OE, et al: Extended duration rivaroxaban versus short-
in thromboembolic stroke. Lancet 1(8649):1215–1220, 1989. term enoxaparin for the prevention of venous thromboembolism after total hip
119. Cosmi B, Rubboli A, Castelvetri C, Milandri M: Ticlopidine versus oral anticoagulation arthroplasty: A double-blind, randomised controlled trial. Lancet 372(9632):31–39,
for coronary stenting. Cochrane Database Syst Rev (4):CD002133, 2001. 2008.
120. Bertrand ME, Rupprecht HJ, Urban P, et al: Double-blind study of the safety of clop- 145. Alexander JH, Lopes RD, James S, et al: Apixaban with antiplatelet therapy after acute
idogrel with and without a loading dose in combination with aspirin compared with coronary syndrome. N Engl J Med 365(8):699–708, 2011.
ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin 146. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al: Apixaban versus enoxaparin for throm-
stent international cooperative study (CLASSICS). Circulation 102(6):624–629, 2000. boprophylaxis in medically ill patients. N Engl J Med 365(23):2167–2177, 2011.

Kaushansky_chapter 25_p0393-0408.indd 408 9/19/15 12:20 AM